IPO Timeline
Broker Results (T-2)
2020-10-22
Some brokers release in afternoon
Grey Market (T-1)
2020-10-23
Afternoon
HKEX Allotment (T-1)
2020-10-23
Evening
Registrar Allotment (T-1)
2020-10-23
Evening
Listing Day (T)
2020-10-27
First day of trading
Company Overview
| Stock Name | 先聲藥業集團有限公司 |
|---|---|
| Stock Code | 02096 |
| Company Full Name | 先聲藥業集團有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要在中國從事藥品研發、生產和商業化，當中以仿制藥為主，專注治療領域包括腫瘤疾病、中樞神經系統疾病及自身免疫疾病。 |
| Listing Date | 2020-10-27 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省南京市玄武區玄武大道699-18號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.simcere.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 13.70 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 41.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 1,784,904,500 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 10.98 |
|---|---|
| First Day Open | HK$ 11.0 |
| First Day Change | -19.85% |
| First Day Volume | 125444000.0 |
| First Day Turnover | 1369320000.0 |
Use of Proceeds
| Use of Proceeds | 1、約60%（或2,035.4百萬港元）將分配予我們在戰略重點治療領域中選定的在研產品的持續研發； 2、約10%（或339.2百萬港元）將分配予加強我們的銷售及營銷能力； 3、約10%（或339.2百萬港元）將分配予我們于未來幾年投資醫藥或生物技術領域的公司，以拓寬我們的產品組合； 4、約10%（或339.2百萬港元）將分配予償還如下表所示的若干未償還銀行貸款； 5、約10%（或339.2百萬港元）將用作營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
摩根士丹利亚洲有限公司 CE AAD291
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (3)
摩根士丹利亚洲有限公司 CE AAD291
中国国际金融香港证券有限公司 CE AEN894
UBS Securities Hong Kong Limited CE BIN466
Joint Bookrunners (4)
摩根士丹利亚洲有限公司 CE AAD291
中国国际金融香港证券有限公司 CE AEN894
UBS Securities Hong Kong Limited CE BIN466
招银国际融资有限公司 CE AVM940
Joint Lead Managers (5)
摩根士丹利亚洲有限公司 CE AAD291
中国国际金融香港证券有限公司 CE AEN894
UBS Securities Hong Kong Limited CE BIN466
招银国际融资有限公司 CE AVM940
信银（香港）资本有限公司 CE AEQ982
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Hillhouse Funds | 387,504,500 HKD | — | 10.86% | — | 6 months | 2021-04-27 |
| 2 | Jericho Capital Master Fund L.P. | 77,500,900 HKD | — | 2.17% | — | 6 months | 2021-04-27 |
| 3 | Lake Bleu Prime Healthcare Master Fund Limited | 193,745,400 HKD | — | 5.43% | — | 6 months | 2021-04-27 |
| 4 | OrbiMed Funds | 193,745,400 HKD | — | 5.43% | — | 6 months | 2021-04-27 |
| 5 | Sage Partners Master Fund | 77,500,900 HKD | — | 2.17% | — | 6 months | 2021-04-27 |
| 6 | 高新(香港)有限公司 | 310,003,600 HKD | — | 8.68% | — | 6 months | 2021-04-27 |
| 7 | 红土创新国际有限公司 | 232,489,000 HKD | — | 6.51% | — | 6 months | 2021-04-27 |
Directors & Management
| Chairman | 任晉生 |
|---|---|
| Company Secretary | 萬玉山,麥寶文 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 任晉生及關連人士(69.15%) |
|---|
IPO Timeline
